MARKET WIREReuters • 2h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
Why AMPH Stock surged +2.28% Today — RQD Quant Desk Flash
$26.93 +2.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $27.11
Amphastar Pharmaceuticals Inc. (AMPH) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (50% profit margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $1.15B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AMPH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AMPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $26.93 (+2.28% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AMPH ranks #85 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AMPH compare to AVLN and RAPP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B- (71/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.14B) and RAPP (Rapport Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AMPH?
▼
Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $27.11 (+0.65%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 16.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMPH)Realized 20D OHLCV Swing Band: ±6.9%
Deterministic 5-Pillar Attribution (71/100 Composite)
🔍 WHY AMPH SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+17/20 pts (24% of score)
FRED Regime × Technicals: 80% of 52W Range • RSI-14 at 66.8 (BULLISH MOMENTUM)
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk11/20 pts (-9 pt drag)
Balance-sheet & 10-K footnote risk deducts 9 pts from forensic ceiling
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$26.62-2.8% Next Q
63
Q2 (-2Q)Grade B-$25.87-2.8% Next Q
66
Q3 (-1Q)Grade B-$25.14+7.1% Next Q
68
CurrentGrade B-$26.93+6.8% Hist 90D α
71
Trajectory: C+ (63) → B- (71)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the AMPH Bull Thesis Could Fail
Even with a 71/100 (B-) score, AMPH faces multiple-compression risk if 11.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 47.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($24.76) or 200D SMA ($22.25) invalidates the momentum regime and cuts Target Base ($28.51) toward Bear Floor ($22.08).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AMPH Stock surged +2.28% Today — RQD Quant Desk Flash
Amphastar Pharmaceuticals Inc. (AMPH) surged +2.28% to $26.93, trading at 80% of its 52-week range ($16.65 – $29.52). High-quality cash engine (50% profit margin, 9% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 80% of its 52-week range ($16.65 – $29.52) with RSI-14 at 66.8 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.9% around $26.93 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 49.5% gross margin and $121.2M annual free cash flow.
Live AMPH Headlines & Catalysts
MARKET WIREReuters • 3h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 5h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 7h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 7h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 9h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 10h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (AMPH Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AMPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.63%▲ ASCENDING CHANNEL
2026-10-30O $27.12H $27.80L $26.76C $26.93VOL 664.5K
RES: $29.94SUP: $25.10SMA50: $24.76SMA200: $22.25
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AMPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
2.0%/yr Implied 5Y Growth
vs. -1.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AMPH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AMPH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMPH)
Health Care Rank #85 of 1016
⚔️ AVLN vs AMPH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AMPH vs. AVLN, RAPP, SPTX, MNKD)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Amphastar Pharmaceuticals Inc. (AMPH) ranks #85 by composite RQD confidence (71/100, grade B-) and #343 by equity capitalization ($1.15B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. AMPH currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AMPH
ACTIVE
Amphastar Pharmaceuticals Inc. | B- | 71/100 | 11.7x | 49.5% | 9.0% | +2.28% | $1.15B | Benchmark Subject |
| AVLN Avalyn Pharma Inc. | D | 49/100 | — | — | — | -0.12% | $1.14B | /avln-vs-amph → |
| RAPP Rapport Therapeutics Inc. | D- | 43/100 | — | — | -22.9% | +7.60% | $1.16B | /rapp-vs-amph → |
| SPTX Seaport Therapeutics Inc. | D+ | 56/100 | — | — | — | +3.53% | $1.13B | /sptx-vs-amph → |
| MNKD MannKind Corporation | C | 63/100 | — | 92.3% | 54.5% | +2.04% | $1.13B | /mnkd-vs-amph → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001297184In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amphastar Pharmaceuticals Inc. (AMPH) reported GAAP revenue of $719.9M (-1.7% vs. FY2024 revenue of $732.0M , and +11.7% cumulative change since FY2023) , GAAP net income of $98.1M, operating cash flow of $156.1M, and free cash flow of $121.2M (-29.7% YoY). On the balance sheet, AMPH closed FY2025 with $1.63B in total assets against $619.7M in total debt (Altman Z-Score: 2.47, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $719.9M | $98.1M | $156.1M | $121.2M | $1.63B | $619.7M |
| FY2024 (FY) | 2024-12-31 | $732.0M | $159.5M | $213.4M | $172.3M | $1.58B | $613.5M |
| FY2023 (FY) | 2023-12-31 | $644.4M | $137.5M | $183.5M | $183.5M | — | — |
3. AMPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AMPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $26.93 (+2.28% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AMPH ranks #85 in composite RQD confidence.
How does AMPH compare to AVLN and RAPP in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B- (71/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.14B) and RAPP (Rapport Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AMPH?
Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AMPH trading relative to its 50-day, 200-day, and 52-week technical levels?
AMPH last traded at $26.93 (+2.28% on volume of 371,432 shares), positioning the stock +8.76% above its 50-day simple moving average ($24.76) and +21.03% above its 200-day simple moving average ($22.25). Across its 52-week range of $16.65 to $29.52, AMPH sits at the 79.9% percentile with a 14-day RSI of 66.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.9% ($25.07 to $28.79).
AMPH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AMPH stock moving today?
Why AMPH Stock surged +2.28% Today — RQD Quant Desk Flash. High-quality cash engine (50% profit margin, 9% return on capital) with steady institutional support.